SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001683168-24-004417
Filing Date
2024-06-21
Accepted
2024-06-21 16:45:16
Documents
14
Period of Report
2024-06-17
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 5.07: Submission of Matters to a Vote of Security Holders
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K phio_8k.htm   iXBRL 8-K 40024
2 2020 PHIO PHARMACEUTICALS CORP. LONG TERM INCENTIVE PLAN, AS AMENDED AND RESTATE phio_ex1001.htm EX-10.1 149175
  Complete submission text file 0001683168-24-004417.txt   397361

Data Files

Seq Description Document Type Size
3 XBRL SCHEMA FILE phio-20240617.xsd EX-101.SCH 3021
4 XBRL LABEL FILE phio-20240617_lab.xml EX-101.LAB 34240
5 XBRL PRESENTATION FILE phio-20240617_pre.xml EX-101.PRE 22363
17 EXTRACTED XBRL INSTANCE DOCUMENT phio_8k_htm.xml XML 3700
Mailing Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752
Business Address 11 APEX DRIVE, SUITE 300A PMB 2006 MARLBOROUGH MA 01752 (508) 767-3861
Phio Pharmaceuticals Corp. (Filer) CIK: 0001533040 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36304 | Film No.: 241061092
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)